Shenzhen Chipscreen Biosciences Co., Ltd. (hereinafter referred to as “Chipscreen Biosciences”) was founded in March 2001 by a team of senior Ph.D. returnee experts from the United States and is a pioneer in the field of original innovative drug development. Adhering to the philosophy of “Constant Innovation For Life,” the company is dedicated to providing patients with affordable, clinically urgent, and revolutionary innovative drugs. Chipscreen Biosciences was the first company to pass the review process of the Science and Technology Innovation Board (STAR Market) and the first biopharmaceutical enterprise listed on the STAR Market (Stock code: 688321.SH).
With a global development strategy based on early-stage research in China, Chipscreen Biosciences has gathered top scientists and teams with extensive experience in related fields and utilizes an integrated technology platform that combines AI-assisted design with chemical genomics. This platform spans the entire process from basic research to clinical translation, enabling the successful development of first-in-class and best-in-class innovative drugs. Currently, the company has two innovative drugs (Chidamide for oncology, Chiglitazar sodium for type 2 diabetes) with multiple indications that are marketed globally, and has established a diversified R&D pipeline with differentiated advantages and global competitiveness in four major areas: malignant tumors, metabolic diseases, autoimmune diseases, and neurodegenerative diseases.
Chipscreen Biosciences has established a global industrial layout comprising the Shenzhen Headquarters/R&D Center/GMP Production Base, Chengdu Regional Headquarters/R&D Center/GMP Production Base, Pengzhou Chipscreen, Beijing Branch, Shanghai Branch, and and its U.S. subsidiary, ThalassaX Therapeutics United States Ltd. Meanwhile, as one of the first national “Innovative Drug Incubation Bases” and a national high-tech enterprise, the company has independently undertaken multiple national “863 Programs”, “10th Five-Year Plan”, “11th Five-Year Plan”, “12th Five-Year Plan”, and “13th Five-Year Plan” Major National Science and Technology Projects, as well as the “Significant New Drug Development” program. It has filed over 800 invention patents in China and abroad, with more than 250 granted.
Strategic Layout
